Context Therapeutics Inc., is a women’s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The company’s robust clinical program for lead candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women’s cancers. Context is headquartered in Philadelphia, PA. For more information, visit www.contexttherapeutics.com.
Location: United States, Pennsylvania, Philadelphia
Member count: 11-50
Total raised: $31.25M
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | Darco Capi... | darcocapit... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 06.12.2021 | - | $31.25M | - | - |
Mentions in press and media 1
| Date | Title | Description | Category | Author | Source |
| 02.08.2022 | Context Th... | Preclinical data support the p... | - | - | en.prnasia... |